1.A retrospective study on the role of postoperative choledochoscopy in the management of retained biliary calculi.
Cruz Ma. Felina P ; Hilvano Serafin C ; De Vera Ramon L ; Arcilla Crisostomo E ; Berberabe A B
Philippine Journal of Surgical Specialties 1998;53(3):113-116
A two-year retrospective study (January 1995 to December 1996) of 328 patients who underwent outpatient postoperative choledochoscopy is reported, 299 patients (91.2%) had retained biliary stones and 90 patients (30.1%) had stones located at the common bile duct. One hundred fourteen patients (46.8%) had primary stones. One hundred fourteen patients (38.1%) with multiple stones found at several locations required an average of 2 postoperative choledochoscopic sessions for complete clearance of biliary tree. Our overall clearance rate was 87 per cent. Only 8 patients (2.54%) had morbidities consisting of hemobilia and pain. (Author)
Human ; Hemobilia ; Common Bile Duct ; Cholelithiasis ; Biliary Tract ; Biliary Tract Surgical Procedures ; Pain
2.Outcomes of hepatic metastasectomy for colorectal cancer metastases in the Philippine General Hospital.
Juan Carlos R. Abon ; Ramon L. De Vera ; A&rsquo ; Ericson B. Berberabe ; Marc Paul J. Lopez
Philippine Journal of Surgical Specialties 2021;76(2):48-55
RATIONALE:
The liver is the most common site of metastasis from
colorectal cancer. Curative intent liver metastasectomy has shown
improvement in overall survival. This manuscript will present
the long-term oncologic outcomes of hepatic metastasectomy for
colorectal cancer with resectable liver metastasis.
METHODS:
Data of patients with resectable liver metastases from
colorectal cancer who underwent hepatic resection at the Philippine
General Hospital over a 10-year period was reviewed. The primary
outcome investigated was overall survival.
RESULTS:
Thirty patients were included in the study. The median
overall survival was 20 months, with a 2-year and 5-year overall
survival rate of 40% and 6.67% respectively. Eleven (36.67%)
patients had disease recurrence, with a median disease-free survival
of 16 months. A significant difference in survival was seen between
patients with synchronous and metachronous liver metastasis (20.38
and 36.78 months respectively, p=0.0393) and in patients given
adjuvant chemotherapy at any time in relation to the occurrence of
the liver metastases versus patients who did not receive any adjuvant
treatment (34.08 and 18.59 months respectively, p=0.0349). Trends
towards improved overall survival were seen in patients 50 years
old or less (36.86 versus 21.78 months, p=0.0837) and in patients
with a clinical risk score of 2 or less (29.65 versus 19.62 months,
p=0.1823), which may show significance in a higher powered study
CONCLUSION
Improved overall survival was observed among patients
with colorectal liver metastases undergoing hepatic metastasectomy
compared to no liver resection.
Metastasectomy
;
Philippines
3.A multicenter randomized clinical trial comparing the clinical efficacy of Imipenem/Cilastin and Ceftazidime plus Metronidazole in surgically treated serious intra-abdominal infections.
Laudico Adriano V ; Cabaluna Nelson D ; Cortez Edgardo R ; Navarro Narciso S ; Erasmo Alex A ; Dela Pe?a Arturo S ; De Vera Ramon L ; Ortega Adelwisa R
Philippine Journal of Surgical Specialties 1994;49(2):47-54
An open, prostective, randomized multicenter clinical trial randomly allocated successive patient who were scheduled for a surgical procedure for serious intra-abdominal infections to receive either treatment CM (ceftazidine plus metronidazole) or monotherapy with treatment IC (imipenem/cilastatin). Out of 90 eligible patients, 87 were clinically evaluable of which 71 were clinically and bacteriologically evaluable (CBE). Cases allocated to each treatment group were comparable as to age, sex, diagnostic group distribution, mean APACHE II scores, and bacteriologic evaluability. Among the 87 clinically evaluable patients, there were 4 (9.1%) and 2 (4.7%) treatment failures among those who received treatments CM and IC respectively (p=0.486). For all eligible patients, the mean fever days was 2.07, mean treatment days was 6.01, and mean hospital days was 11.57, and was not significantly different between the two treatment groups. Among clinically evaluable cases, the mean APACHE II scores of patients with succesful outcomes (5.8) was very significantly lower (p=0.000) than that of patients whose treatment failed (13.8). This was also true for CBE cases. Logistic regression analysis showed that among six variables (diagnostic group, APACHE II score, antibiotic used, fever days, hospital days and treatment days) only the APACHE II score signficantly contributed to treatment failure (p=0.001).
Human ; Cilastatin ; Imipenem ; Metronidazole ; Drug Combinations ; Sex Distribution ; Age Distribution ; Intraabdominal Infections ; Anti-bacterial Agents